Welander

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022
Autoantibody, Kidney bean, Nasdaq Stockholm, Disease, Immunoglobulin A, IgA nephropathy, Nasdaq, Chronic kidney disease, Environment, Barratt, Therapy, Kidney, Nationwide, Caregiver, Mortality, Gut, A, Diagnosis, American depositary receipt, CALT, GLOBE, Online gambling, Pharmaceutical industry, Welander

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022
IgA nephropathy, Nasdaq, Peyer, Primary, Kidney disease, Kidney, Social conditions in Honduras, USD, Company, Partnership, Ministry, Immunoglobulin A, Degenerative disease, Mortality, Autoantibody, CALT, NDA, Nasdaq Stockholm, News, Ileum, Infection, Budesonide, Doctor of Philosophy, Patient, Gut, Kidney bean, Peyer's patch, Terminology, HKEX, A, Therapy, Nationwide, CMC, Pharmaceutical industry, MD, Welander, Food

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.